UNIPHAR PLC EO -,08 Logo
IE00BJ5FQX74
A2PNWJ
UPR.L

UNIPHAR PLC EO -,08

Caricamento quotazioni...

Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Uniphar increases profit in H1 2026 and confirms EBITDA target for 2028

    Uniphar reports adjusted EPS of EUR 0.109 in H1 2026 (+11.2%), gross profit of EUR 236.5m (+7.7%) and EBITDA of EUR 61.1m (+6.2%). Return on capital employed (ROCE) was 14.7%, and free cash flow was negative at EUR -47m, which is attributed to timing effects in working capital. Management reaffirmed the mid‑term target of EUR 200m EBITDA by 2028 and expects double‑digit growth in Pharma and continued growth in Medtech; the commissioning of the new Greenogue 2 distribution centre has been delayed to February 2027. » Altro su de.investing.com


  • Uniphar executives trade shares from remuneration plan

    Senior executives of Uniphar carried out share purchases and sales under the company’s share-based remuneration plan through the Uniphar plc Employee Benefit Trust. CEO Gerard Rabbette bought 111,088 ordinary shares and sold 233,068 ordinary shares; CFO Timothy Dolphin bought 74,059 and sold 155,378 ordinary shares — all transactions at €3.8629 per share. After the transactions Rabbette holds 7,334,772 and Dolphin holds 5,610,856 ordinary shares. The dealings were reported on Euronext Dublin via Intertrust Trustee (Ireland) Limited as trustee and are based on a disclosure under Article 19 of the Market Abuse Regulation. » Altro su de.investing.com


  • Uniphar schedules general meeting for 7 May and sends annual report

    Uniphar has scheduled its annual general meeting for 7 May 2026 at 11:00 in the premises of William Fry LLP in Dublin and has sent the annual report for the year ended 31 December 2025 to shareholders. Shareholders may attend in person, vote by proxy, or follow the meeting by telephone as listeners only; questions must be submitted in writing with the shareholder reference number by 5 May 2026 at 17:00. The notice, proxy form and annual report are available on the company website and for inspection at the registered office during normal business hours. » Altro su de.investing.com


  • Uniphar reports 9% organic gross profit growth and beats 2025 earnings expectations

    Uniphar recorded 9% organic gross profit growth in 2025 and adjusted earnings per share that rose by around 21%, outperforming the 14% consensus forecast. Drivers included lower financing costs and effects from a €35m share buyback programme. Net debt at year-end stood at 1.5x EBITDA, roughly €90m below analyst expectations, supported by positive working capital. Uniphar confirms its target to reach €200m EBITDA by 2028 (including €20m from M&A) and sets 2026 growth targets for its divisions: Pharma (double-digit), Medtech (high single-digit) and Supply Chain & Retail (low single-digit); the new logistics centre and ERP remain on schedule for the summer. » Altro su de.investing.com


  • Santhera agrees exclusive distribution deal for AGAMREE with Uniphar for five GCC states

    Santhera Pharmaceuticals has signed an exclusive distribution partnership with Uniphar for AGAMREE (Vamorolone) in the United Arab Emirates, Saudi Arabia, Kuwait, Oman and Bahrain; sales via a named-patient program are due to start in Q1 2026, with broader commercial distribution expected after approval at the end of 2026. Santhera will receive sales-based compensation and stresses that the agreement is intended to accelerate access to the therapy for DMD patients in the region. The drug is already approved in several regions and Santhera names additional licensing partners for certain markets. » Altro su finanzen.net

Nel 2026, UNIPHAR PLC EO -,08 ha già distribuito 0,0205 € di dividendi. L'ultimo pagamento è avvenuto a ottobre.

Dati finanziari dell'azienda

Nell'ultimo trimestre, UNIPHAR PLC EO -,08 ha registrato ricavi pari a 1,57 Mld € e un utile netto di 19,73 Mln €
(EUR) giugno 2026
YoY
Ricavi 1,57 Mld -
Utile lordo 216,56 Mln -
Utile netto 19,73 Mln -
EBITDA 57,87 Mln -

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
1,13 Mld €
Numero di azioni
259,57 Mln
Massimo/minimo a 52 settimane
5,14 € - 3,53 €
Rendimento da dividendo
0,47%
Dividendi TTM
0,0205 €
Beta
1,16
Rapporto P/E
21,01
Rapporto PEG
-1,31
Rapporto P/B
2,62
Rapporto P/S
0,36

Profilo aziendale

Uniphar plc opera come società diversificata di servizi sanitari nella Repubblica d'Irlanda, nel Regno Unito e a livello internazionale. La società opera attraverso tre divisioni: Commercial & Clinical, Product Access e Supply Chain & Retail. La divisione Commercial & Clinical offre servizi esternalizzati di vendita, marketing e gestione multicanale degli account ai produttori farmaco-medicali, nonché servizi di distribuzione e supporto ai produttori di dispositivi medici. La divisione Product Access fornisce servizi on demand, che garantiscono l'accesso a prodotti e trattamenti farmaco-medicali sviluppando relazioni e interazioni di valore tra i produttori e gli altri stakeholder del settore sanitario; e servizi di accesso esclusivo, che offrono partnership di distribuzione su misura ai partner farmaceutici per marchi chiave. La divisione Supply Chain & Retail si occupa di distribuzione pre-grossistica e grossistica di prodotti farmaceutici, sanitari e per la salute animale verso farmacie, ospedali e veterinari; e gestisce una rete di farmacie con i marchi Life, Allcare e Hickey's. Offre inoltre supporto farmaceutico, gestione della catena di approvvigionamento farmaceutica, assistenza infermieristica specialistica e infusionale, distribuzione di dispositivi medici, tecnologie sanitarie, data intelligence e servizi di consulenza, consulenza farmaceutica, medical affairs e servizi di farmacia online e product fostering, oltre a soluzioni di dati per l'industria farmaceutica. Uniphar plc è stata fondata nel 1967 ed ha sede a Dublino, in Irlanda.

Nome
UNIPHAR PLC EO -,08
CEO
Gerard Rabbette
Sede centrale Dublin, du
Irlanda
Sito web
Quotazione in borsa
17/07/2019
Dipendenti 3500

Simboli di borsa

Borsa Simbolo
London Stock Exchange
UPR.L
Frankfurt
0NR.F
London
UPR.L
München
0NR.MU
Düsseldorf
0NR.DU
🍪

Parqet  usa i cookie. Scopri di più